Alara Awarded NIH SBIR - Direct to Phase II Grant for Radiology Innovation

Press release
September 21, 2023

September 21, 2023 – Alara is proud to announce the receipt of a Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH), demonstrating our commitment to radiological excellence and patient safety. This federal grant, amounting to $1,973,174, will fund the advancement of clinical applications for the Alara Gateway, the company’s flagship software product to advance medical imaging.

The NIH selectively awards grants to support projects that exhibit potential for significant impact in the healthcare sector. “Our team appreciates the NIH’s recognition and support. Receiving this grant is a vote of confidence from one of the most respected health research organizations in the world,” states Nate Mazonson, CEO and co-founder of Alara. “We are poised to leverage this grant and other resources to further enhance the security, efficiency, and effectiveness of patient care delivery.”

As part of Alara’s commitment to improving radiology quality, we have developed CMS patient safety measures in partnership with the University of California San Francisco (UCSF). These measures ensure radiation doses do not exceed evidence-based thresholds for Computed Tomography (CT) exams. Alara’s gateway ingests and processes the necessary data for measure calculation, minimizing reporting burden on hospitals and clinicians. Alara’s HIPAA and SOC-II compliant software is uniquely constructed to support the clinical, operational, and financial objectives of health systems, allowing for the possibility of more modern technology applications to be used in a clinical setting while simultaneously enhancing the security of patient data.

We extend our gratitude to the NIH, our partners, and our team at E.B. Howard Consulting who played an important role in the application process. 


About Alara

Alara was founded to usher in a new wave of medical imaging advancements that will improve patient outcomes. Alara’s quality measures have been endorsed by the National Quality Forum, which evaluates the scientific merit and feasibility of quality measures, and have been incorporated into CMS quality payment programs. To learn more about Alara’s mission and gateway solution, please visit Alara’s website.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R44CA287536. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.